Value proposition

Multi-target cell and gene therapies for unmet medical needs.

Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation.
After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow.
In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis.
Our pipeline also includes Inflammation, at discovery stage.

Cell and gene therapy, Recombinant Live Biotherapeutic, Chronic wounds, Oncology, Advanced Therapy Medicinal Product, Inflammation, and Oncolytic Bacteria